Clinical trial

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

NCT05853432

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2022-03-16

PhaseN/A

Study timeline

Study start (actual)2022-03-16Date precision: day

Registry last updated2023-05-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HR+/HER2- Advanced or Metastatic Breast Cancerunresolved

Interventions

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

DublinIreland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05853432 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.